Compare · MURF vs NVO
MURF vs NVO
Side-by-side comparison of Murphy Canyon Acquisition Corp. (MURF) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both MURF and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO carries a market cap of $220.35B.
- NVO has hit the wire 5 times in the past 4 weeks while MURF has been quiet.
- NVO has more recent analyst coverage (25 ratings vs 0 for MURF).
- Company
- Murphy Canyon Acquisition Corp.
- Novo Nordisk A/S
- Price
- -
- -
- Market cap
- -
- $220.35B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2022
- News (4w)
- 0
- 5
- Recent ratings
- 0
- 25
Murphy Canyon Acquisition Corp.
Murphy Canyon Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. It intends to focus on identifying businesses in the real estate industry, including construction, homebuilding, real estate owners and operators, arrangers of financing, insurance, and other services for real estate, and adjacent businesses and technologies targeting the real estate space. The company was incorporated in 2021 and is based in San Diego, California.
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest MURF
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form SC 13G/A filed by Murphy Canyon Acquisition Corp. (Amendment)
- SEC Form S-8 filed by Murphy Canyon Acquisition Corp.
- SEC Form 424B3 filed by Murphy Canyon Acquisition Corp.
- SEC Form EFFECT filed by Murphy Canyon Acquisition Corp.
- SEC Form 4 filed by Lewis-Hall Freda C
- SEC Form 4 filed by Mcnealey Jennifer Isacoff
- SEC Form 4 filed by Bligh James
- SEC Form 4 filed by Farley Chele Chiavacci
Latest NVO
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Wolfe Research initiated coverage on Novo Nordisk A/S